Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia

References

• Rowley J D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Jenster G, Ten H J, Zovich D, Pattengale P K, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251–253
   PubMed Web of Science ®Google Scholar
• Daley G Q, Van Etten R A, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Pear W S, Miller J P, Xu L, Pui J C, Soffer B, Quackenbush R C, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780–3792
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Gutterman J U, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990–998
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007; 13: 1089–1097
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004; 18: 641–656
   PubMed Web of Science ®Google Scholar
• Gambacorti C, Talpaz M, Sawyers C L, Druker B J, Hochhaus A, Schiffer C, et al. Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory/intolerant of interferon-α. Blood 2005; 106: 1089
   Web of Science ®Google Scholar
• Druker B J, Guilhot F, O'Brien S, Larson N, on behalf of the IRIS (International Randomized IF). Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol 2006; 24(Suppl 18S)6506
   Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver R T, Druker B J, Goldman J M, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
   PubMed Web of Science ®Google Scholar
• Talpaz M, Goldman J, Sawyers C, Hochhaus A, Silver R T, Smith B D, et al. High dose imatinib (STI571, Gleevec) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC): follow-up of the phase II studies. Blood 2003; 102: 3369
   Google Scholar
• Graham S M, Jorgensen H G, Allan E, Pearson C, Alcorn M J, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325
   PubMed Web of Science ®Google Scholar
• Marley S B, Deininger M W, Davidson R J, Goldman J M, Gordon M Y. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000; 28: 551–557
   PubMed Web of Science ®Google Scholar
• Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997; 272: 33260–33270
   PubMed Web of Science ®Google Scholar
• Danhauser-Riedl S, Warmuth M, Druker B J, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589–3596
   PubMed Web of Science ®Google Scholar
• Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker A J, Corey S J. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999; 13: 855–861
   PubMed Web of Science ®Google Scholar
• Lionberger J M, Wilson M B, Smithgall T E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581–18585
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Corey S J, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227–34239
   PubMed Web of Science ®Google Scholar
• Hu Y, Swerdlow S, Duffy T M, Weinmann R, Lee F Y, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870–16875
   PubMed Web of Science ®Google Scholar
• Ptasznik A, Nakata Y, Kalota A, Emerson S G, Gewirtz A M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187–1189
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453–461
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Lin H, Arlinghaus R, Aggarwal B B, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672–677
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J, Kong L Y, Meng F, Lee F, Talpaz M. Constitutive activation of SRC-family kinases in chronic myelogenous leukemia patients resistant to imatinib mesylate in the absence of BCR-ABL mutations: a rationale for use of SRC/ABL dual kinase inhibitor-based therapy. Blood 2005; 106: 1087
   Google Scholar
• Faderl S, Kantarjian H M, Thomas D A, Cortes J, Giles F, Pierce S, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000; 36: 263–273
   PubMed Web of Science ®Google Scholar
• Lugo T G, Pendergast A M, Muller A J, Witte O N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079–1082
   PubMed Web of Science ®Google Scholar
• Van Etten R A. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004; 28(Suppl 1)S21–S28
   PubMed Web of Science ®Google Scholar
• Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci P G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764–773
   PubMed Web of Science ®Google Scholar
• Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 1999; 96: 12804–12809
   PubMed Web of Science ®Google Scholar
• Gordon M Y, Dowding C R, Riley G P, Goldman J M, Greaves M F. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987; 328: 342–344
   PubMed Web of Science ®Google Scholar
• Bedi A, Zehnbauer B A, Barber J P, Sharkis S J, Jones R J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038–2044
   PubMed Web of Science ®Google Scholar
• Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, Vaganay S, et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001; 97: 2084–2090
   PubMed Web of Science ®Google Scholar
• Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki M O, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795–806
   PubMed Web of Science ®Google Scholar
• Abram C L, Courtneidge S A. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000; 254: 1–13
   PubMed Web of Science ®Google Scholar
• Boggon T J, Eck M J. Structure and regulation of Src family kinases. Oncogene 2004; 23: 7918–7927
   PubMed Web of Science ®Google Scholar
• Li S. Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert Opin Ther Targets 2005; 9: 329–341
   PubMed Web of Science ®Google Scholar
• Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9: 2043–2059
   PubMed Web of Science ®Google Scholar
• Lowell C A, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev 1996; 10: 1845–1857
   PubMed Web of Science ®Google Scholar
• Overell R W, Watson J D, Gallis B, Weisser K E, Cosman D, Widmer M B. Nature and specificity of lymphokine independence induced by a selectable retroviral vector expressing v-src. Mol Cell Biol 1987; 7: 3394–3401
   PubMed Web of Science ®Google Scholar
• Watson J D, Eszes M, Overell R, Conlon P, Widmer M, Gillis S. Effect of infection with murine recombinant retroviruses containing the v-src oncogene on interleukin 2- and interleukin 3-dependent growth states. J Immunol 1987; 139: 123–129
   PubMed Web of Science ®Google Scholar
• Anderson S M, Carroll P M, Lee F D. Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle. Oncogene 1990; 5: 317–325
   PubMed Web of Science ®Google Scholar
• Engelman A, Rosenberg N. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation. Mol Cell Biol 1990; 10: 4365–4369
   PubMed Web of Science ®Google Scholar
• Keller G, Wagner E F. Expression of v-src induces a myeloproliferative disease in bone-marrow-reconstituted mice. Genes Dev 1989; 3: 827–837
   PubMed Web of Science ®Google Scholar
• Meyn M A, III, Wilson M B, Abdi F A, Fahey N, Schiavone A P, Wu J, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281: 30907–30916
   PubMed Web of Science ®Google Scholar
• Wilson M B, Schreiner S J, Choi H J, Kamens J, Smithgall T E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002; 21: 8075–8088
   PubMed Web of Science ®Google Scholar
• Tanis K Q, Veach D, Duewel H S, Bornmann W G, Koleske A J. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol 2003; 23: 3884–3896
   PubMed Web of Science ®Google Scholar
• Klejman A, Schreiner S J, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall T E, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766–5774
   PubMed Web of Science ®Google Scholar
• Ptasznik A, Urbanowska E, Chinta S, Costa M A, Katz B A, Stanislaus M A, et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med 2002; 196: 667–678
   PubMed Web of Science ®Google Scholar
• Ilaria R L, Jr, Hawley R G, Van Etten R A. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999; 93: 4154–4166
   PubMed Web of Science ®Google Scholar
• Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui A L, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 1999; 18: 4754–4765
   PubMed Web of Science ®Google Scholar
• Kieslinger M, Woldman I, Moriggl R, Hofmann J, Marine J C, Ihle J N, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 2000; 14: 232–244
   PubMed Web of Science ®Google Scholar
• Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley P W, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664–672
   PubMed Web of Science ®Google Scholar
• Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi J K, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151–6161
   PubMed Web of Science ®Google Scholar
• Druker B J, Sawyers C L, Kantarjian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042
   PubMed Web of Science ®Google Scholar
• Ottmann O G, Druker B J, Sawyers C L, Goldman J M, Reiffers J, Silver R T, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321–1331
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann W G, Pellicena P, Schindler T, Veach D R, Miller W T, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236–4243
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller W T, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938–1942
   PubMed Web of Science ®Google Scholar
• Azam M, Latek R R, Daley G Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831–843
   PubMed Web of Science ®Google Scholar
• Chu S, Xu H, Shah N P, Snyder D S, Forman S J, Sawyers C L, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093–2098
   PubMed Web of Science ®Google Scholar
• Tipping A J, Baluch S, Barnes D J, Veach D R, Clarkson B M, Bornmann W G, et al. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 2004; 18: 1352–1356
   PubMed Web of Science ®Google Scholar
• Azam M, Daley G Q. Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006; 10: 67–76
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145: 913–923
   PubMed Web of Science ®Google Scholar
• O'hare T, Walters D K, Stoffregen E P, Jia T, Manley P W, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505
   PubMed Web of Science ®Google Scholar
• Shah N P, Tran C, Lee F Y, Chen P, Norris D, Sawyers C L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401
   PubMed Web of Science ®Google Scholar
• Tokarski J S, Newitt J A, Chang C Y, Cheng J D, Wittekind M, Kiefer S E, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790–5797
   PubMed Web of Science ®Google Scholar
• Lee F Y, Lombardo L, Camuso A, Castaneda S, Fager K, Flefleh C, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 2005; 46: 159, (abstr. 675)
   Google Scholar
• Lombardo L J, Lee F Y, Chen P, Norris D, Barrish J C, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng J Q, Zhang S, Lee J H, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185–9189
   PubMed Web of Science ®Google Scholar
• Schittenhelm M M, Shiraga S, Schroeder A, Corbin A S, Griffith D, Lee F Y, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473–481
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah N P, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541
   PubMed Web of Science ®Google Scholar
• Baccarani M, Kantarjian H M, Apperley J F, Lipton J H, Druker B, Countouriotis A, et al. Efficacy of dasatinib (SPRYCEL) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 START-C phase II study. Blood 2006; 108(Suppl.)164
   Google Scholar
• Cortes J, Kim D W, Guilhot F, Rosti G, Silver R T, Gollerkeri A, et al. Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA180-005 START-A phase II study. Blood 2006; 108(Suppl.)2160
   Google Scholar
• Martinelli G, Hochhaus A, Coutre S, Apperley J F, Shah N, Gollerkeri A, et al. Dasatinib (SPRYCEL) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i). Blood 2006; 108(Suppl.)745
   PubMed Web of Science ®Google Scholar
• Dombret H, Ottman O G, Rosti G, Simonsson B, Larson R A, Gollerkeri A, et al. Dasatinib (SPRYCEL) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): updated results from the CA180-015 START-L study. Blood 2006; 108(Suppl.)286
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143–5150
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Branford S, Radich J, Mueller M C, Shah N, Erben P, et al. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. J Clin Oncol 2007; 25(Suppl 18S)7023
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109: 497–499
   PubMed Web of Science ®Google Scholar
• Larson R, Ottmann O, Kantarjian H, le Coutre P, Baccarani M, Weitzman A, et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol 2007; 25(Suppl 18S)7040
   Google Scholar
• Druker B J. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 354: 2594–2596
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Talpaz M, O'Brien S, Smith T L, Giles F J, Faderl S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res 2002; 8: 2177–2187
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Shan J, Smith T, Talpaz M, Kozuch P, Rios M B, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer 2001; 92: 2501–2507
   PubMed Web of Science ®Google Scholar
• Marin D, Marktel S, Bua M, Szydlo R M, Franceschino A, Nathan I, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon α. Leukemia 2003; 17: 1448–1453
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios M B, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 2004; 10: 68–75
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Schiffer C, Sawyers C L, Hochhaus A, Guilhot F, Niederwieser D W, et al. Imatinib (Gleevec) maintains favorable long-term outcomes in chronic-phase chronic myeloid leukemia (CML) for patients failing interferon-α (IFN) follow-up of a phase II study. Blood 2003; 102: 3368
   Web of Science ®Google Scholar
• Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, et al. Imatinib produces significantly superior molecular responses compared to interferon α plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003; 17: 2401–2409
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, O'Brien S, Jones D, Borthakur G, Nicaise C, et al. Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP). Haematologica 2007; 92(Suppl 1)0360
   Google Scholar